Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;202(4):e27-e30.
doi: 10.1111/bjh.18916. Epub 2023 Jun 5.

Effects of pyruvate kinase activators on red blood cell properties in sickle cell disease

Philippe Joly  1   2   3 , Elie Nader  2   3 , Flora Ketels  2   3 , Camille Boisson  1   2   3 , Romain Carin  2   3 , Céline Renoux  1   2   3 , Alexandra Gauthier  2   3   4 , Solene Poutrel  2   3   5 , Yves Bertrand  4 , Philippe Connes  2   3
Affiliations

Effects of pyruvate kinase activators on red blood cell properties in sickle cell disease

Philippe Joly et al. Br J Haematol. 2023 Aug.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Grace RF, Rose C, Layton DM, Galacteros F, Barcellini W, Morton DH, et al. Safety and efficacy of mitapivat in pyruvate kinase deficiency. N Engl J Med. 2019;381:933-44.
    1. Yang H, Merica E, Chen Y, Cohen M, Goldwater R, Kosinski PA, et al. Phase 1 single- and multiple-ascending-dose randomized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first-in-class allosteric activator of pyruvate kinase R, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8:246-59.
    1. Charache S, Grisolia S, Fiedler AJ, Hellegers AE. Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia. J Clin Invest. 1970;49:806-12.
    1. Rab MAE, Bos J, van Oirschot BA, van Straaten S, Kosinski PA, Chubukov V, et al. Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy. Blood. 2021;137:2997-3001.
    1. van Dijk MJ, Rab MAE, van Oirschot BA, Bos J, Derichs C, Rijneveld AW, et al. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study. Am J Hematol. 2022;97:E226-9.

Publication types

Substances

LinkOut - more resources